Report Company Directory
- Fast Forward No. 754 by William Blair
- Autolus Aucatzyl secures UK MHRA approval in r/r adult ALL, all eyes on 1Q25 by KBC Securities
- Morning Notes : AKZA NA, ARGX BB, TWEKA NA, DEME BB, AUTL US, MRUS US by KBC Securities
- Fast Forward No. 753 by William Blair
- Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) by GlobeNewsWire
- Morning Notes : FLOW NA, FUR NA, GLPG NA, KIN BB, KPN NA, XFAB FP, AZE BB, IMCD NA, ONWD BB, AUTL US, EXO NA, ZEAL DC, PHVS US by KBC Securities
- Autolus R&D day outlines SLE data and path to market, MS up next by KBC Securities
- Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event by GlobeNewsWire
- Takeaways From R&D Day; Overall Promising Start for I&I Franchise With Pivotal Path and Expansion Plans by William Blair
- R&D Day Quick Take: Company Outlines Accelerated Approval Path in Lupus Nephritis After 50% CRR in Phase I by William Blair